PD L1 News and Research

RSS

Siblings with unique gene mutation offer insights into type 1 diabetes treatment

Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.

18 Apr 2024

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances.

13 Apr 2024

Blood-based DNA test spares bladder cancer patients from unnecessary treatments

Testing for tumor DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows.

4 Apr 2024

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

26 Mar 2024

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status

New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age or menopausal status.

20 Mar 2024

Gut bacteria strains could be the key to predicting cancer treatment success

Researchers discovered that gut microbiota strains can predict the effectiveness and adverse effects of immune checkpoint blockade (ICB) therapy in rare cancer patients.

6 Mar 2024

Study finds metabolic checkpoint PHGDH as potential target to modulate tumor-associated macrophages

A study by a scientific team from the University of Vienna and the MedUni Vienna, recently published in the top-class journal Cellular & Molecular Immunology, has a promising result from tumor research: The enzyme phosphoglycerate dehydrogenase (PHDGH) acts as a metabolic checkpoint in the function of tumor-associated macrophages (TAMs) and thus on tumor growth.

27 Feb 2024

Comprehensive analysis of immune checkpoint inhibitors reveals endocrine toxicity patterns

Announcing a new publication for Acta Materia Medica journal. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose a challenge of immune-related adverse events (irAEs), particularly endocrine toxicity, that can severely compromise patient well-being.

21 Feb 2024

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

Novel three-drug combo shows promise in advanced HER2-negative breast cancer treatment

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

14 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.

27 Jan 2024

Lung cancer prediction using biomarkers based on bronchoalveolar fluid microbiomes

The lung microbiomes of patients with benign and malignant pulmonary diseases.

23 Jan 2024

High-resolution map of the neuroblastoma immune landscape points to new target for immunotherapy

A detailed 'atlas' of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for Pediatric Oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells.

4 Jan 2024

Researchers identify the culprit responsible for harmful inflammation in certain muscular disorders

Inflammation is an important part of the body's defenses, eliminating threats and repairing damage. When the immune system is overactivated, though, it can turn from friend to foe.

14 Dec 2023

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Simple bean diet intervention demonstrates significant prebiotic effects

The impact of incorporating canned navy beans into the regular diet for eight weeks.

5 Dec 2023

Research paves way for clinical trials of existing drugs for brain metastasis

The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer and for which licensed drugs could be clinically trialled to find out if they could treat the disease.

29 Nov 2023

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Dietary components that impact anti-tumor immunity.

28 Nov 2023

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

From Cell Signaling Technology 23 Nov 2023